NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH

AI Briefing

• – NovelMed Therapeutics announces regulatory clearance for Ruxoprubart for subcutaneous administration.
• – Phase II results show positive efficacy and safety in intravenous monotherapy for PNH treatment.
• – Subcutaneous Ruxoprubart achieves transfusion independence for patients with PNH.